Abstract:AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) is a potent aminopyrimidine tyrosine kinase (TK) inhibitor, which is active at nanomolar concentrations against c-Kit, PDGFR as well as the wild type Bcr-Abl and common variety of mutant Bcr-Abl (e.g., M351T, F317L and E255V) TK. In a previous report, we demonstrated that treatment with the hydroxamic acid analogue histone deacetylase inhibitor LBH589 (Novartis) (20 to 100 nM) induces hsp90 acetylation and promotes polyubiquitylation and proteasomal degradation of Bcr-Abl, which is associated with apoptosis of the cultured Bcr-Abl expressing human chronic myeloid leukemia-blast crisis (CML-BC) K562 and LAMA-84 cells, as well as of primary CML-BC cells. In the present studies, we determined the cell cycle and apoptotic effects of AMN107 and/or LBH589 in K562, LAMA-84 and primary CML-BC cells. Treatment with AMN107 (20 to 100 nM) induced cell cycle G1 phase accumulation and apoptosis, exerting 10 to 20 fold more potent effect than imatinib mesylate (IM) in K562 and LAMA-84 cells. This was associated with marked induction of p27, inhibition of Bcr-Abl TK activity, as well as attenuation of the levels of p-STAT5, p-AKT, Bcl-xL, and c-Myc levels in a dose dependent manner. Co-treatment with LBH589 (50 nM) and AMN107 (100 nM) induced more G1 phase accumulation than either agent alone. The combination of AMN107 and LBH589 also exerted synergistic apoptotic effects in K562 cells, as determined by the median effect isobologram analysis. This was associated with more attenuation of the levels of pro-growth and pro-survival proteins, e.g., p-STAT5, p-ERK1/2, c-Myc and Bcl-xL, as well as greater induction of the levels of pro-death p27 and Bim proteins. Treatment of human AML HL-60 cells containing ectopic expression of the IM-refractory, mutant Bcr-AblT315I with LBH589 (50 nM for 24 hours) attenuated the mutant Bcr-Abl levels and induced apoptosis of HL-60/Bcr-AblT315I cells. Treatment with AMN107 (up to 2.0 μM) alone was ineffective in inducing loss of viability of HL-60/Bcr-AblT315I cells, and co-treatment with LBH589 (50 nM) and AMN107 did not induce more loss of cell viability of HL-60/Bcr-AblT315I cells than treatment with LBH589 alone. AMN107 levels ≥ 200 nM significantly inhibited survival of HL-60/Bcr-AblE255K and HL-60/Bcr-AblM351T cells. Consistent with this, the combined treatment with LBH589 and AMN107 also induced more loss of viability than treatment with either agent alone in 4 samples of IM-refractory primary CML-BC cells. These studies demonstrate that both AMN107 and LBH589 are active against IM-resistant CML-BC and the combination of the two exerts superior activity against IM-sensitive and IM-resistant, wild type and mutant Bcr-Abl expressing cultured and primary CML cells.

Endoplasmic Reticulum Stress-Mediated Apoptosis In Imatinib-Resistant Leukemic K562-R Cells Triggered By Amn107 Combined With Arsenic Trioxide

Arsenic Circumvents the Gefitinib Resistance by Binding to P62 and Mediating Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer

Coordination of Intrinsic, Extrinsic, and Endoplasmic Reticulum-Mediated Apoptosis by Imatinib Mesylate Combined with Arsenic Trioxide in Chronic Myeloid Leukemia.

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

Effects of Arsenic Trioxide on Cell Proliferation and Apoptosis and bcr-abl Gene Expression in Imatinib-resistant K562 Cells

Arsenic Trioxide Enhances STI571-Induced Apoptosis of K562 Cells Through Downregulating Bcl-XL and Bcr-Abl.

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

The Experimental Investigation of Arsenic Trioxide Reverse Imatinib Mesylate Resistance in K562/MDR1

Arsenic Trioxide Potentiates Gilteritinib-induced Apoptosis in FLT3-ITD Positive Leukemic Cells Via IRE1a-JNK-mediated Endoplasmic Reticulum Stress

Single Nucleotide Polymorphisms in Apoptosis Pathway Are Associated with Response to Imatinib Therapy in Chronic Myeloid Leukemia

Synergistic Cytotoxicity from Combination of Imatinib and Platinum-Based Anticancer Drugs Specifically in Bcr-Abl Positive Leukemia Cells.

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

Effect of Arsenic Trioxide on Cell Cycle Progression of Cell Line KBM5R with T315I Point Mutation

Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways

Synthetic Lethality of Combined AT-101 with Idarubicin in Acute Myeloid Leukemia Via Blockade of DNA Repair and Activation of Intrinsic Apoptotic Pathway.

Arsenic Trioxide and Proteasome Inhibitor Bortezomib Synergistically Induce Apoptosis in Leukemic Cells: the Role of Protein Kinase Cδ

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy

Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

CX‑5461 Potentiates Imatinib‑induced Apoptosis in K562 Cells by Stimulating KIF1B Expression.